## **ALERT CARD**

## Important safety information Lojuxta® ▼ capsules (lomitapide)

This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get.

If you get any side effects, talk to your healthcare professional.

This includes any possible side effects not listed in the Patient Information Leaflet (PIL). In the UK, you can also report side effects directly via the Yellow Card Scheme at https://vellowcard.mhra.gov.uk/

By reporting side effects, you can help provide more information on the safety of this medicine. Side effects should also be reported to Chiesi Limited on

0800 0092329 or e-mail: PV.UK@chiesi.com

Please see section 4.5 of the Summary of Product Characteristics for the list of interactions with other medicines before giving the person named on this card any further medications. If you need to report an adverse event/ side effect, please contact: 0800 0092329 or e-mail: PV.UK@chiesi.com

Patient's name:
Doctor's name:
Doctor's phone number:
Date Lojuxta treatment started:

## Information for the doctor or pharmacist

This patient has been prescribed Lojuxta. Lojuxta could interact with the following drugs:

- CYP 3A4 inhibitors
  CYP 3A4 inducers
- · Coumarin anticoagulants
- Statins
- P-gp substrates
- Oestrogen-containing oral contraceptives

Go to https://www.medicines.org.uk/emc to access the lomitapide SmPC.

## Important safety information



Please keep this card with you at all times.

Show this card to any doctor or pharmacist involved in your treatment.

Please make sure that you have a list of all your other medicines with you, including herbal and non prescription medicines, when you visit your doctor or pharmacist.

UK-LOJ-2400014 — Date of preparation: October 2024